Advertisement
U.S. markets open in 40 minutes

HUTCHMED (China) Limited (HCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
17.38-0.03 (-0.17%)
At close: 04:00PM EST
17.74 +0.36 (+2.07%)
Pre-Market: 08:00AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close17.41
Open17.41
Bid17.31 x 100
Ask17.46 x 100
Day's Range17.16 - 17.74
52 Week Range11.93 - 21.92
Volume99,926
Avg. Volume93,215
Market Cap3.035B
Beta (5Y Monthly)0.75
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateFeb 26, 2025 - Mar 03, 2025
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.53
  • GlobeNewswire

    HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

    — Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZA

  • GlobeNewswire

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. Dr Hu has over 20 years of experience in the development of therapeutic antibodies, antibody-drug conjugates, and vaccines. Throughout her caree